Bcl10 Antibody (151): sc-56023
- Bcl10 Antibody (151) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against amino acids 122-168 of Bcl10 of human origin
- recommended for detection of Bcl10 of mouse, rat and human origin by WB, IP, IF and IHC(P)
- See Bcl10 (331.3): sc-5273 for Bcl10 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for Bcl10 Antibody (151) for WB and IHC(P) applications. These reagents are now offered in bundles with Bcl10 Antibody (151) (see ordering information below).
QUICK LINKS
SEE ALSO...
Bcl10 Antibody (151) is a mouse monoclonal IgG1 antibody that detects Bcl10 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Bcl10, also known as CIPER, c-CARMEN, and mE10, plays a crucial role in the regulation of apoptosis and immune responses, primarily through involvement in the NFκB signaling pathway. Bcl10 contains an N-terminal caspase recruitment domain (CARD), which is essential for function in activating NFκB via a NIK-dependent mechanism. This activation influences various cellular processes, including inflammation and cell survival. While Bcl10 promotes apoptosis through CARD-mediated oligomerization, Bcl10 has also been shown to facilitate the processing of caspase-9 into active dimer form, further underscoring importance in apoptotic signaling. Despite association with certain tumor types, Bcl10 is not frequently mutated in many human tumors and lymphomas, indicating that expression and functional integrity may be critical for maintaining normal cellular homeostasis. Anti-Bcl10 antibody (151) is an invaluable tool for researchers investigating the complex roles of Bcl10 in cellular signaling and disease mechanisms.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Bcl10 Antibody (151) References:
- Lack of BCL10 mutations in multiple myeloma and plasma cell leukemia. | Shih, LY., et al. 2001. Genes Chromosomes Cancer. 30: 402-6. PMID: 11241793
- The Bcl10/Malt1 signaling pathway as a drug target in lymphoma. | Jost, P., et al. 2006. Curr Drug Targets. 7: 1335-40. PMID: 17073595
- BCL10 down-regulation in peripheral T-cell lymphomas. | Rossi, M., et al. 2012. Hum Pathol. 43: 2266-73. PMID: 22818167
- BCL10 regulates RNF8/RNF168-mediated ubiquitination in the DNA damage response. | Zhao, H., et al. 2014. Cell Cycle. 13: 1777-87. PMID: 24732096
- Bcl10 synergistically links CEACAM3 and TLR-dependent inflammatory signalling. | Sintsova, A., et al. 2018. Cell Microbiol. 20: PMID: 28886618
- Bcl10 is associated with actin dynamics at the T cell immune synapse. | Wagh, K., et al. 2020. Cell Immunol. 356: 104161. PMID: 32768663
- TRIM41 is required to innate antiviral response by polyubiquitinating BCL10 and recruiting NEMO. | Yu, Z., et al. 2021. Signal Transduct Target Ther. 6: 90. PMID: 33640899
- BCL10 loss-of-function novel mutation leading to atypical severe combined immunodeficiency. | Al-Tamemi, S., et al. 2022. Clin Immunol. 241: 109067. PMID: 35750252
- Regulation mechanisms of CARMA1-Bcl10-MALT1 complex assembly inferred from the analysis of TRAF6-deficient cells. | Inoue, K., et al. 2023. Genes Cells. 28: 411-421. PMID: 36871192
- CARMA3 Drives NF-κB Activation and Promotes Intervertebral Disc Degeneration: Involvement of CARMA3-BCL10-MALT1 Signalosome. | Liu, Y., et al. 2024. Inflammation. 47: 1936-1951. PMID: 38607566
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bcl10 Antibody (151) | sc-56023 | 200 µg/ml | $322.00 | |||
Bcl10 Antibody (151): m-IgG Fc BP-HRP Bundle | sc-539025 | 200 µg Ab; 10 µg BP | $361.00 | |||
Bcl10 Antibody (151): m-IgG1 BP-HRP Bundle | sc-541213 | 200 µg Ab; 20 µg BP | $361.00 |